INFIMEDIC: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
INFIMEDIC
Largest movements
- Cash +€7,141
up €7,141 (+13.4%), from €53,154 to €60,295
mainly Depreciation (+€6,905) and Receivables within one year (+€6,390)
- Receivables within one year -€6,390
down €6,390 (-97.6%), from €6,549 to €159
of which Other amounts receivable: -€4,390
- Tangible fixed assets +€5,480
up €5,480 (+51.9%), from €10,551 to €16,031
- Profit (loss) carried forward +€6,024
up €6,024 (+9.7%), from €62,389 to €68,413
- Trade debts +€2,350
up €2,350 (+153.6%), from €1,530 to €3,880
- Tax, wage and social debts -€1,405
no longer reported in 2025 (was €1,405)
of which Remuneration and social security: -€1,000
- Staff costs +€21,577
up €21,577 (+24.5%), from €88,097 to €109,674
- Depreciation -€3,980
down €3,980 (-36.6%), from €10,885 to €6,905
- Gross operating margin +€3,966
up €3,966 (+3.3%), from €119,883 to €123,849
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €70,254 | €77,223 | +€6,969 | +9.9% |
| Fixed assets | 21/28 | €10,551 | €16,031 | +€5,480 | +51.9% |
| Tangible fixed assets | 22/27 | €10,551 | €16,031 | +€5,480 | +51.9% |
| Furniture and vehicles | 24 | €10,551 | €16,031 | +€5,480 | +51.9% |
| Current assets | 29/58 | €59,703 | €61,192 | +€1,489 | +2.5% |
| Amounts receivable within one year | 40/41 | €6,549 | €159 | -€6,390 | -97.6% |
| Trade receivables | 40 | €2,000 | - | -€2,000 | |
| Other amounts receivable | 41 | €4,549 | €159 | -€4,390 | -96.5% |
| Cash at bank and in hand | 54/58 | €53,154 | €60,295 | +€7,141 | +13.4% |
| Deferred charges and accrued income | 490/1 | - | €738 | +€738 | |
| Total equity and liabilities | 10/49 | €70,254 | €77,223 | +€6,969 | +9.9% |
| Equity | 10/15 | €67,319 | €73,343 | +€6,024 | +8.9% |
| Reserves | 13 | €4,930 | €4,930 | = | 0.0% |
| Profit (loss) carried forward | 14 | €62,389 | €68,413 | +€6,024 | +9.7% |
| Amounts payable | 17/49 | €2,935 | €3,880 | +€945 | +32.2% |
| Amounts payable within one year | 42/48 | €2,935 | €3,880 | +€945 | +32.2% |
| Trade debts | 44 | €1,530 | €3,880 | +€2,350 | +153.6% |
| Suppliers | 440/4 | €1,530 | €3,880 | +€2,350 | +153.6% |
| Taxes, remuneration and social security | 45 | €1,405 | - | -€1,405 | |
| Taxes | 450/3 | €405 | - | -€405 | |
| Remuneration and social security | 454/9 | €1,000 | - | -€1,000 | |
| Remuneration, social security and pensions | 62 | €88,097 | €109,674 | +€21,577 | +24.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €10,885 | €6,905 | -€3,980 | -36.6% |
| Other operating charges | 640/8 | €893 | €699 | -€194 | -21.7% |
| Gross operating margin | 9900 | €119,883 | €123,849 | +€3,966 | +3.3% |
| Operating profit (loss) | 9901 | €20,008 | €6,571 | -€13,437 | -67.2% |
| Financial income | 75/76B | - | €420 | +€420 | |
| Recurring financial income | 75 | - | €420 | +€420 | |
| Financial charges | 65/66B | €218 | €681 | +€463 | +212.4% |
| Recurring financial charges | 65 | €218 | €681 | +€463 | +212.4% |
| Profit (loss) for the period before taxes | 9903 | €19,790 | €6,310 | -€13,480 | -68.1% |
| Income taxes | 67/77 | €485 | €286 | -€199 | -41.0% |
| Profit (loss) for the period | 9904 | €19,305 | €6,024 | -€13,281 | -68.8% |
| Profit (loss) for the period to be appropriated | 9905 | €19,305 | €6,024 | -€13,281 | -68.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 September 2026 via checked.be.